title: Detection of dynamic frequencies of Th17 cells and their associations with clinical parameters in patients with systemic lupus erythematosus receiving standard therapy.
abstract: Recent evidence implicated an important role of Th17 cells in the pathogenesis of systemic lupus erythematosus (SLE). However, the association between dynamic changes of Th17 cell frequency and clinical parameters in SLE patients receiving clinical managements remains unknown. Here, we sought to evaluate their correlation in Chinese new-onset SLE patients with standard therapy. We found that the frequency of Th17 cells was higher in SLE patients than that in healthy controls and could be decreased by standard care. In consistent, the level of serum IL-6, IL-1β, IL-23, and Stat3 activity was elevated in SLE patients and down-regulated by disease treatment. Of note, the frequency of Th17 cells was correlated with SLEDAI and serum C3 in SLE patients. The changes of Th17 cell frequency were associated with those of SLEDAI and serum C3 in SLE patients between pretreatment and posttreatment. Further, the Th17 cell frequency was positively correlated with serum anti-dsDNA antibody in SLE patients. The changes of Th17 cell frequency were associated with those of serum anti-dsDNA antibody in SLE patients. Our findings showed that dynamic frequencies of Th17 cells were closely correlated with clinical parameters in SLE patients receiving standard treatment, which could facilitate the efficient management and development of novel therapeutics for SLE.
authors.affiliation: Institute for Immunobiology, Shanghai Medical College of Fudan University, Shanghai, 200032, China.
authors.forename: Zhenke
authors.initials: Z
authors.lastname: Wen
authors.forename: Lin
authors.initials: L
authors.lastname: Xu
authors.forename: Wei
authors.initials: W
authors.lastname: Xu
authors.forename: Sidong
authors.initials: S
authors.lastname: Xiong
mesh_terms: D000328:Adult; D000906:Antibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001799:Blood Sedimentation; D016022:Case-Control Studies; D002452:Cell Count; D049109:Cell Proliferation; D002738:Chloroquine / Q000627:therapeutic use*; D003176:Complement C3 / Q000378:metabolism; D004247:DNA / Q000276:immunology; D004185:Disability Evaluation; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D012720:Severity of Illness Index; D058504:Th17 Cells / Q000473:pathology*
chemical_list: D000906:Antibodies; D015415:Biomarkers; D003176:Complement C3; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D002738:Chloroquine; D004247:DNA